From the Editor

Oct 01, 2007
Pharmaceutical Executive
FDA has just premiered a new newsletter on drug safety. There's just one little problem....
Sep 01, 2007
Pharmaceutical Executive
In this issue, a longtime contributor to this magazine, former FDA official, and generally thoughtful, knowledgeable person concludes his excellent three-part series on drug safety with a look at how risk is communicated to patients and doctors. It's a fine, detailed, subtle piece of work, and I recommend it to you. (See "Failure to Communicate".)
Jul 03, 2007
Pharmaceutical Executive
The Acomplia story isn't ending. It's just beginning. Get ready to see what happens when a much-desired drug is marketed by people accountable to no one.
Jun 01, 2007
Pharmaceutical Executive
It's not FDA's job to make doctors and patients take more responsibility for using drugs wisely. But whose job is it? Really, whose?
Mar 01, 2007
Pharmaceutical Executive
There are good reasons why we shouldn't permit lifestyle drugs on the market. But as a society, we've already shown that those reasons don't mean much to us.
Feb 01, 2007
Pharmaceutical Executive
A new bill says HHS has to negotiate Medicare drug prices with pharma companies. It won't work—but that's not the biggest thing wrong with it.
Jan 01, 2007
Pharmaceutical Executive
A new GAO report sets out to explain why drug development is so expensive and what to do about it. What the report says is important, but what it leaves out is a sense of how the world of pharma actually works.
Dec 01, 2006
Pharmaceutical Executive
To one major legal scholar, drug safety regulation isn't just about meeting standards, it's about what you take away from one group of patients in order to benefit the rest.
Nov 01, 2006
Pharmaceutical Executive
The US Department of Justice thinks that "Average Wholesale Price" should mean just what the words say—no more, no less. Why? It's never meant that before.
Oct 01, 2006
Pharmaceutical Executive
The problem isn't that there's conflict between safety and efficacy or between getting a useful medicine to market and protecting the public from a dangerous one. The problem is that the conflict isn't well structured. That needs to change.
native1_300x100
lorem ipsum